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ABSTRACT 
Oral cancer accounts for a significantly higher percentage of all cancer cases. Survival rates of oral cancers are relatively low in comparison to other 
major cancers, although incidence rates are as low as 3%. Oral cancer is the most common cancer among Indian males and third most common 
cancer among Indian females. Delay in diagnosis, metastases, and the presence of secondary tumors are the major reasons for the poor prognosis of 
oral cancers. Innocuous potentially malignant lesions have higher chances for malignant transformation and early diagnosis of these lesions is 
necessary for improving survival rates. The patient’s overall outcome can be enhanced through early diagnosis and management of these potentially 
malignant lesions, as the risk factors are well documented for oral cancers. Currently available clinical diagnostic tools developed for the early 
detection of oral cancers includes toluidine blue dye (TB) (tolonium chloride), Oral brush biopsy, chemiluminescence using Vizilite, salivary 
diagnostics, and several imaging devices such as Velscope and multispectral optical imaging systems. This paper provides a detailed review about 
the various diagnostic aids in the detection of oral cancers and also emphasizes a dentist’s role in combating this dreadful entity. 
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INTRODUCTION 
Head and neck cancers are among the sixth most common human 
cancers [1], and constitute 3% of all types of cancers [2]. Oral cavity 
is the site of oral cancer in 48% of cases, and oral squamous cell 
carcinoma (SCC) accounts for 90% of these cancers. The annual 
incidence of oral squamous cell carcinoma is more than 300,000. 
Annual incidence recorded in the United States, Europe and Japan is 
35,000 [2]; 40,000 and 10915 respectively [4]. The tongue is the 
most common site for intraoral carcinomas, constituting around 
40% of all cases in the oral cavity proper with the posterior-lateral 
border and ventral surfaces of the tongue being the most common 
sites. Second-most common intraoral site is the floor of the mouth, 
whereas the gingival mucosa, buccal mucosa, labial mucosa, and 
hard palate are less frequently involved. Recent studies have shown 
an increasing trend of head and neck cancers, particularly tongue 
cancer in young adults. Suspected etiological factors include tobacco 
and its products, drug abuse, environmental factors, and human 
papilloma virus [5]. Oral carcinomas show high mortality rates with 
approximately 9,000 deaths every year. Oral cancers may kill one 
person, every hour, every day and is more dangerous than breast 
cancer, cervical cancer, and prostate cancer [6].  
The American Cancer Society’s screening protocol for all head and 
neck cancers (including oral cancers) states that asymptomatic 
individuals between the ages of 20 and 40 should be screened every 
three years and asymptomatic patients after the age of 40 should be 
screened annually. High risk individuals, such as smokers and 
alcohol users should be examined every year, regardless of their age 
[7]. The detection of oral cancer in early stages is quite difficult and 
any procedure that facilitates the visualization of suspicious lesions 
may be fruitful in early detection. Alterations in the surface texture, 
integrity, color, size or contour, and mobility of structures indicates 
a suspicion for oral leukoplakia or squamous cell carcinoma [8]. Red 
or white lesions or a long standing ulceration is the characteristic 
clinical appearances of pre-malignant lesions or malignancies. 
However, as only a small fraction of these lesions undergo malignant 
change and an oral examination unfortunately fails to distinguish 
between lesions that are potentially dangerous from lesions that are 
benign. Hence, the recent advancements in oral cancer research in 
the development of potentially useful diagnostic tools at the clinical 
and molecular levels for the early detection of oral cancers are of 
outmost importance. However, tissue biopsy along with pathologic 
assessment remains the gold standard for oral cancer diagnosis [9]. 
Variousclinical diagnostic tools developed for the early detection of 
oral cancer include the following- 
1. Vital staining (toluidine blue dye, lugol’s iodine staining, 
methylene blue staining)  
2. Oral CDx brush biopsy kits 
3. Chemiluminescence (vizilite) 
4. Tissue fluorescence imaging (Velscope system) 
5. Tissue fluorescence spectroscopy 
6. Salivary biomarkers 
7. Optical coherence tomography 
8. DNA ploidy 
9. Biopsy  
Till date, the above mentioned diagnostic aids are not equivalent or 
superior to visual inspection and examination [10, 11]. 
DISCUSSION 
Potentially useful diagnostic tools for the early detection of oral 
cancer are the result of advancements in oral cancer research. 
Various diagnostic tools in the clinical and molecular levels are-  
Vital staining (toluidine blue) 
Tolonuim chloride also known as Toluidine blue, (TB) has been used 
in the past for the detection of mucosal abnormalities of the cervix 
and the oral cavity. TB is an acidophilic metachromatic dye that has 
an affinity to selectively stain the acidic tissue components, sulfate, 
carboxylate and phosphate radicals such as DNA and RNA, but not 
normal mucosa. Proposed mechanism of action is-  
(a) Nuclei of malignant cells have an increased uptake of the dye, 
and this manifests as increased DNA synthesis.  
(b) Rapid dye penetration through randomly arranged tumor cells. 
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The patient is asked to rinse the mouth with the dye and the 
physician then inspects for the areas of blue staining. Depending on 
the degree of dysplasia, malignant lesions stain dark blue and 
dysplastic lesions stain different shades of blue [8]. Blue staining in a 
patient is indicative of biopsy. Occasionally, the normal mucosa may 
retain a small amount of dye, which can be wiped away with acetic 
acid. Rough or keratinous surfaces (e. g., the dorsum of the tongue, 
gingival crevices) may also retain the stain. Non-malignant areas of 
inflammation occasionally stain with toluidine blue. It is mandatory to 
re-stain all positive lesions within 14 days to decrease the false 
positive rate. Patients with previous carcinoma of the upper aero 
digestive tract can be screened with the use of TB. These patients are 
at high recurrence risk; therefore, clinicians may add toluidine rinses 
to their visual examination [8, 12]. TB is highly sensitive and 
moderately specific for malignant lesions, it is far less sensitive for pre-
malignant lesions and a false negative rate of up to 58% has been 
reported. The various steps of TB staining are summarized in fig. 1a-d.  
 
 
Fig. 1a: Suspected innocuous lesion 
 
 
Fig. 1b: Application of 1% toluidine blue dye 
 
 
Fig. 1c: Neutralization with 1% acetic acid 
 
 
Fig. 1d: Retention of blue color, indicative of malignant lesion 
fig. reference 1a-1d- 
Lugol’s iodine staining 
Italian Camillo Golgi introduced this stain. Lugol’s Iodine solution is 
formed by two grams of iodine and four grams of potassium iodide 
in 100 cc of distilled water. After recording the clinical features and 
photography of the clinically suspicious lesions, 1% acetic acid is 
applied to the lesional tissue for 20 Sec and then rinsed with water. 
Later, another photograph is taken following the application of 
Lugol’s iodine at the lesion with a cotton bud for 10-20s. 
Lesions showing brown stain is considered as positive while lesions 
without any retention of stain are considered as negative [13]. The 
glycogen content present in the normal epithelium forms the basis 
of selective staining of the intact mucosa with Lugol's iodine. This 
selective staining helps in differentiating the inflammatory or 
carcinomatous epithelium from the normal epithelium where the 
glycogen content is low [14-16]. 
Staining with TB along with Lugol’s iodine (Double staining 
technique) helps in differentiating the inflammatory lesions. This 
helps in the clinical determination of the degrees of differentiation of 
malignant lesions because poorly differentiated malignant lesions 
without glycogen content do not show Lugol’s iodine retention. Pre 
therapeutic assessment of biologic aggressiveness of the disease can 
also be made by this double staining technique. Depending on the 
retention of the dyes, the biopsy site can be determined [17]. Double 
staining technique is also used for high risk patients and selecting 
biopsy sites for patients with wide field cancers [18]. 
Oral brush biopsy 
OralCDx (OralScan Laboratories, Inc.) is a computer-assisted oral 
biopsy system that collects trans-epithelial cellular samples. [fig. 2a]. 
This system contains a specialized brush for the brush biopsy, a 
glass slide, a form, a fixative (alcohol/ polyethylene glycol), and a 
container for sending samples to the CDx laboratory [19]. [fig. 2b]. The 
procedure involves placement of the brush on the lesion and rotating 
it for 5-10 times till it produces reddening or haemorrhagic spots [fig. 
2c]. The obtained cell material is placed on a dry slide, fixed, and sent 
for analysis [20-22]. [fig. 2d]. Highly keratinized leukoplakia is a 
contraindication for the use of this method, as it does not allow enough 
basal cells to be gathered. Also, inflammatory conditions frequently 
give atypical results. TB is a fast and relatively simple procedure that 
does not cause bleeding or require anesthesia. Currently, the 
technique is combined with molecular analysis. This increases its 
specificity and permits the identification of genetic anomalies, such as 
mutations of the tumor suppressing gene p53, epigenetic alterations, 
and genomic instability. Reported sensitivity values ranged from 
71.4% to 100% and specificity from 32% to 100%. 
 
 
Fig. 2a: Trans-epithelial biopsy system 
 
 
Fig. 2b: Oral brush biopsy brush 
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Fig. 2c: Placement of brush on the mucosa, and 5-15 times 
rotation to obtain trans-epithelial biopsy 
 
 
Fig. 2d: Transfer of cells onto glass slide 
 
Chemiluminescence (Vizilite) 
Chemiluminescence by definition is the emission of light from a 
chemical reaction [23]. Vizilite, a diagnostic tool for the early 
detection of oral cancer is based on the principle of 
chemiluminescence [fig. 3]. The kit contains 1% acetic acid solution, 
a capsule with an outer shell of flexible plastic and an inner vial of 
fragile glass, and a retractor [22]. Activation requires breakage of 
the glass vial by bending the capsule. This permits the chemical 
products to react and produce a bluish-white light with a wave 
length of 430-580 nm that lasts for around 10 min [24]. The 
procedure involves a one-minute mouthwash with 1% acetic acid 
solution. Under diffuse bluish-white chemiluminescent light, normal 
mucosa absorbs the light and appears blue, whereas the light is 
reflected by abnormal cells with a higher nucleus: cytoplasm ratio 
and by epithelium with excessive keratinization, 
hyperparakeratinization, and / or significant inflammatory infiltrate, 
which appear acetowhite with brighter, more marked, and more 
distinguishable borders [25-27]. ViziLite® system enhances the 
clinician’s ability to detect oral lesions, particularly white lesions 
and those with white and red areas. The sharp borders between 
normal and abnormal oral mucosa is easily delineated by ViziLite 
plus. Also, the borders observed usually extended beyond than those 
detected in the visual examination [8, 27]. The majority of these 
lesions can be diagnosed with incandescent light, and that 
mouthwash with acetic acid allowed the additional detection of 
some lesions [25]. The reported sensitivity is 100% and the 
specificity ranges from 0%-14.2%. 
 
 
Fig. 3: Chemiluminescence with vizilite 
Tissue fluorescence imaging (Velscope system) 
Use of tissue autofluorescence has been used for the screening and 
diagnosis of pre-cancerous and early cancers of the lung, uterine 
cervix, and skin. More recently, it has been used in the oral cavity. 
The changes in the structure and metabolism of the epithelium and 
sub-epithelial stroma alter their interaction with intense blue light 
(400 to 600 nm) [10, 28]. Velscope system is a tissue fluorescence 
imaging system used for inspection of the oral mucosa [10, 12, 29]. 
[fig. 4]. Under the intense blue light (400 to 600 nm), normal oral 
mucosa emits a green auto-fluorescence, whereas abnormal areas 
absorb the fluorescent light and appear dark. Hence, early detection 
of pathological lesions is possible by detecting the early biochemical 
changes even before their evident appearance. Velscope system 
seems to be very promising due to its ability and effectiveness in 
identifying the visually occult lesions and lesion margins that are 
occult to visual examination under white light [29]. The sensitivity 
values range from 97% to 98% and specificity from 94% to 100%. 
 
 
Fig. 4: Autofluorescence with velscope 
 
Tissue fluorescence spectroscopy 
This system consists of a small optical fiber that produces various 
excitation wavelengths and a spectrograph that receives records and 
analyzes the spectra of reflected fluorescence from the tissue [10, 
12, 29]. This technique accurately distinguishes malignant lesions 
from healthy oral mucosa with high sensitivity and specificity [10, 
12, 29]. As the optical fiber can sample only a small mucosal area, 
this technique is not suitable to detect new lesions or to demarcate 
large lesions [29],thus limiting the use of spectroscopy for 
evaluating well-defined small mucosal lesions that has been already 
diagnosed through clinical inspection, with the attempt to clarify its 
benign or (pre) malignant nature [fig. 5a and b]. 
 
 
Fig. 5a: Suspected lesion 
 
 
Fig. 5b: Spectroscopy revealing green color, suggestive of 
malignancy 
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Salivary biomarkers 
Saliva may be used as a diagnostic tool for molecular biomarkers for 
oral cancer detection. Saliva is a mirror of the body and reflects normal 
and disease states and its use as a diagnostic fluid meets the demands 
of an economic, easy to collect and non-invasive diagnostic tool.  
Saliva, as a diagnostic tool, has many merits over serum- 
• Saliva collection is a non-invasive procedure. 
• Non costly 
• Large populations can be screened.  
Measurement of specific salivary macromolecules and examination 
of proteomic or genomic targets such as enzymes, cytokines, growth 
factors, metalloproteinase, endothelin, telomerase, cytokeratins, 
mRNAs, and DNA transcripts can be done by the saliva [23-32]. Cyfra 
21-1, TPS, carcino-embryonic antigen (CEA), SCC, CA125, and CA19-
9 are the most studied epithelial serum circulatory tumor markers 
in the saliva of carcinoma patients.  
Optical coherence tomography 
Optical coherence tomography (OCT) is a non-invasive tomographic 
imaging modality. The technique detects areas of inflammation, 
dysplasia, and cancer by recording subsurface reflections to build a 
cross-sectional architectural image of the tissue. Contrast 
enhancement of the images may be done with the use of surface 
plasmon resonant gold nanoparticles [33]. The imaging range of OCT 
technology suitable for the oral mucosa is with a tissue penetration 
depth of 1 mm to 2 mm [34-36]. 
DNA ploidy 
DNA ploidy measures the nuclear DNA content. The cytological 
samples after staining with Feulgen dye are compared against a 
reference group of cells, and a computer-assisted analysis identifies 
deviations of cellular DNA content. Cancer progression is 
contributed by genomic instability, and dysplastic lesions are 
distinguished by abnormal DNA content [37]. 
Biopsy 
Scalpel or punch biopsy and histopathology remains the gold 
standard for diagnosis of potentially malignant disorders. The 
diagnosis of mild and moderate dysplasias and determination of 
early-stage invasion of carcinoma in situ (CIS) or squamous cell 
carcinomas (SCC) is dependent upon the variations amongst the 
pathologist’s findings [38, 39]. Adequate sampling of oral lesions is 
an important factor for the histopathological diagnosis of oral SCC. 
Histopathological changes may be seen even when visual 
examination fails to detect an oral lesion clinically (e. g. “Field 
cancerization,”) [40].  
CONCLUSION 
Potentially malignant disorders pose an important threat to the 
overall survival of an individual. Oral health professionals play a 
major role in early detection and treatment of these disorders, thus 
combating these dreadful lesions and improving the prognosis. A 
wide variety of diagnostic aids are currently available which are 
used for early detection of these disorders. 
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